## **Lupus Enrollment Form**



Fax Referral To: 1-855-297-1270

Address: 6020 Ave Roberto Sanchez Vilella Carolina, PR 00982

Phone: 1-888-280-1190

NCPDP: 4026325

Six Simple Steps to Submitting a Referral **PATIENT INFORMATION** (Complete or include demographic sheet) Preferred Contact Methods: Phone (to primary # provided below) Text (to cell # provided below) Email (to email provided below) Note: Carrier charges may apply. By providing the phone number(s) and email address above, you are consenting to receive automated calls, emails and/or text messages from CVS Specialty® about your prescription(s), account, and health care. Standard data rates apply. Message frequency varies. If unable to contact via text or email, Specialty Pharmacy will attempt to contact by phone. \_\_\_\_\_ Last Four of SSN: \_\_\_\_\_ Primary Language: \_\_\_\_\_\_ Parent/Caregiver/Legal Guardian Name (Last, First): Relationship to patient: 2 PRESCRIBER INFORMATION Prescriber's Name: \_\_\_\_\_ State License #: \_\_\_\_\_\_ 

 Address:
 \_\_\_\_\_\_ City, State, ZIP Code:

 Phone:
 \_\_\_\_\_\_ Contact Person:
 \_\_\_\_\_\_ Contact's Phone:

 INSURANCE INFORMATION Please fax copy of prescription and insurance cards with this form, if available (front and back) Is the Patient Insured? ☐ Yes ☐ No Is the Patient enrolled or eligible for Medicare/Medicaid? ☐ Yes ☐ No Policy Holder's Name:\_\_\_\_\_\_ Policy Holder's DOB:\_\_\_\_\_ Relationship to Patient:\_\_\_\_\_ Medical Insurance: \_\_\_\_\_ Telephone: \_\_\_\_\_ Policy ID: \_\_\_\_\_ Group #: \_\_\_\_\_ Prescription Plan Telephone: Prescription Insurance: Policy ID: \_\_\_\_\_\_ RX BIN #: \_\_\_\_\_ RX PCN #:\_\_\_\_ 4 DIAGNOSIS AND CLINICAL INFORMATION Needs by Date: \_\_\_\_\_Ship to: Datient Office Other: \_\_\_\_\_ Diagnosis (ICD-10): M32.1 Systemic lupus erythematosus (SLE) M32.11 Endocarditis in systemic lupus erythematosus M32.12 Pericarditis in systemic lupus erythematosus M32.13 Lung involvement in systemic lupus erythematosus M32.14 Glomerular disease in systemic lupus erythematosus M32.15 Tubulo-interstitial nephropathy in systemic lupus erythematosus M32.19 Other organ or system involvement in systemic lupus erythematosus M32.8 Other forms of systemic lupus erythematosus M32.9 Systemic lupus erythematosus, unspecified Other Code: \_\_\_\_\_ Description: \_\_\_\_ **Patient Clinical Information:** Allergies: \_\_\_\_\_ Weight: \_\_\_\_lb/kg Height: \_\_\_\_in/cm
Positive ANA or anti-dsDNA test? \[ \text{Yes} \] No Date of test: \_/\_/\_\_ Specialty pharmacy to coordinate injection training/home health nurse visit as necessary? Tyes No Site of Care: MD office Infusion Clinic Outpatient Health Home Health Injection training not necessary. Date training occurred: \_\_\_

Reason: MD office training patient Pt already independent Referred by MD to alternate trainer

**Lupus Enrollment Form** 

	Please Co	omplete Patient an	d Prescriber Information	
atient Name:		Patient DOE	3:Patient Phone:	
atient Address:				
escriber Name:			Prescriber Phone:	
atient Clinical II	nformation:			
llergies:	Weight: _		lb/kg Height	t:In/cm
PRESCRIPT	ION INFORMATION			
MEDICATION	STRENGTH		OOSE & DIRECTIONS	QUANTITY/REFILL
□ Benlysta SC	200 mg/mL PEN (approved for use in patients 5 yrs. and older)  200 mg/mL PFS (adult use only)	☐ Inject 200mg SC Patients 5 yrs and o ☐ Inject 200mg SC Lupus Nephritis(LN LN Adult Induction d	Ider with SLE 15 kg to < 40 kg: once every 2 weeks ) Dosing: ose: // 200 mg injections) once weekly for 4	Quantity: 1 package (4 doses) Refills:
☐ Benlysta IV	☐ 120 mg/5 mL vial ☐ 400 mg/20 mL vial	☐ Induction Dose: 10 mg/kg IV (Dose =mg) at 2 week intervals for the first 3 doses and at 4-week intervals thereafter. Infuse IV over 1 hour.  ☐ Maintenance Dose: 10 mg/kg (Dose =mg) every 4 weeks Infuse IV over 1 hour ☐ 300 mg IV over a 30-minute period, every 4 weeks		Quantity: vials Refills: Quantity: vials
_ <u></u>	300 mg/2 mL (150 mg/mL)	Other:		Refills:
Other:	Other:	Other:		Quantity:
Patient is interested in	patient support programs	STAMP SIGNATURE NO		Refills:
Dispense As Written" / AW / May Not Substitu	Brand Medically Necessary / Do Not Subtete	stitute / No Substitution /	May Substitute / Product Selection Permitted / Substitution Permissible	
	ature:			
A MA NC & DD: Interc	hange is mandated unless Prescriber writes t	the words "No Substitution"	ATTN: New York and Iowa provide	rs, please submit electronic prescrip

The information provided above is true and accurate to the best of my knowledge, with supporting documentation in the patient's medical record. By signing above, I hereby authorize CVS Specialty Pharmacy and/or its affiliate pharmacies to complete and submit prior authorization (PA) requests to payors for the prescribed medication for this patient and to attach this Enrollment Form to the PA request as my signature.

CONFIDENTIALITY NOTICE: This communication and any attachments may contain confidential and/or privileged information for the use of the designated recipients named above. If you are not the intended recipient, you are hereby notified that you have received this communication in error and that any review, disclosure, dissemination, distribution or copying of it or its contents is prohibited. If you have received this communication in error, please notify the sender immediately by telephone and destroy all copies of this communication and any attachments.

Plan member privacy is important to us. Our employees are trained regarding the appropriate way to handle members' private health information. This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Specialty and/or one of its affiliates.